The DEGs found in HER2+ breast cancer patients sensitive and resistant to neoadjuvant chemotherapy were mainly related to plasma membranes, vesicles, and extracellular space and were involved in different biological processes, such as cellular response to chemical stimulus, cell adhesion, and signal regulation. This evidence concerns the gene ERBB2 and breast carcinoma.